{
  "system": "hedgefund",
  "title": "Hedge Fund Edge Tracker",
  "updated_at": "2026-02-15T07:05:13.113396+00:00",
  "total_positions": 38,
  "active_count": 0,
  "publish_count": 0,
  "watch_count": 0,
  "killed_count": 29,
  "pending_count": 9,
  "total_pnl": 0,
  "win_rate": 0,
  "best_trade": 0,
  "worst_trade": 0,
  "short_count": 15,
  "long_count": 13,
  "recent_positions": [
    {
      "asset": "Kyndryl: adverse financial disclosures and litigat",
      "ticker": "KD",
      "direction": "SHORT",
      "confidence": 69.0,
      "band": "A",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "Kyndryl's Filing Delay Is a Control-Risk Event: The Discount Can Persist Until t",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "Faruqi & Faruqi, LLP: securities litigation",
      "ticker": "IHE",
      "direction": "SHORT",
      "confidence": 58.0,
      "band": "B",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "The Plaintiff-Bar Distribution Machine Is Back: Lawsuit SEO Can Extend a Sector ",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "State of Connecticut: antitrust litigation",
      "ticker": "AMRX",
      "direction": "SHORT",
      "confidence": 55.0,
      "band": "B",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "Generic-Drug Antitrust Never Dies: Procedural Wins Can Reprice Liability Tails f",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "Gallagher Re: reinsurance capacity",
      "ticker": "AJG",
      "direction": "LONG",
      "confidence": 53.0,
      "band": "C",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "Reinsurance Is Softening, But Complexity Can Still Be a Broker's Friend: AJG Get",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "Harmony Biosciences, LLC: litigation procedure",
      "ticker": "HRMY",
      "direction": "LONG",
      "confidence": 48.0,
      "band": "C",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "Harmony's Real Story Is the 2030 Generic Date: Procedure Noise Is Background, IP",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "Steward Health Care System: litigation and financi",
      "ticker": "ELV",
      "direction": "SHORT",
      "confidence": 46.0,
      "band": "C",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "Steward's Trustee Is Naming Names: Even Small-Dollar Payer Suits Can Add Scrutin",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "Akums Drugs & Pharma: industry financials and stra",
      "ticker": "AKUMS.NSE",
      "direction": "LONG",
      "confidence": 64.0,
      "band": "B",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "Akums is building a regulated-market runway - EU-GMP plus a long-dated Europe co",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "First Solar: corporate governance and compliance",
      "ticker": "FSLR",
      "direction": "SHORT",
      "confidence": 62.0,
      "band": "B",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "First Solar\u2019s \u2018fraud probe\u2019 looks like litigation-headline plumbing - still a le",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "Immunic, Inc.: clinical studies",
      "ticker": "IMUX",
      "direction": "LONG",
      "confidence": 60.0,
      "band": "B",
      "entry_price": null,
      "current_pnl": null,
      "state": "PENDING",
      "headline": "Immunic\u2019s long game: execution de-risking now, real value event end-2026 - and t",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "Awaiting due diligence"
    },
    {
      "asset": "Alo Yoga: litigation (no instrument)",
      "ticker": "",
      "direction": "MIXED",
      "confidence": 31.0,
      "band": "E",
      "entry_price": null,
      "current_pnl": null,
      "state": "KILLED",
      "headline": "Alo Yoga Litigation: A Real Lawsuit With No Listed Handle Means It's Not a Trade",
      "publish_headline": "",
      "kill_reason": "",
      "state_reason": "No investable instrument"
    }
  ],
  "report_url": "https://ivanmassow.github.io/hedgefund-tracker/"
}